Sabra Health Care REIT's strong fundamentals, 6.62% dividend yield, and low forward multiple make it an attractive investment amid tariff uncertainties and potential recession. The REIT's solid growth in FFO, AFFO, and revenue, driven by increased occupancy rates and NOI growth, highlights its resilience in a challenging economic environment. Sabra's well-positioned balance sheet, with robust liquidity and deleveraging efforts, ensures stability and growth potential, even during economic downturns.
Sabra Health Care REIT, Inc. offers a 6.7% dividend yield, benefiting from strong fundamentals, favorable demographics, and a well-managed balance sheet. Management is guiding for AFFO growth, supported by rising occupancy, stable reimbursement rates, and a robust acquisition pipeline in skilled nursing. SBRA stock trades at a reasonable valuation with a forward P/FFO of 12.2, positioning it for potential market-beating total returns.
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q4 2024 Earnings Conference Call February 20, 2025 1:00 PM ET Company Participants Lukas Hartwich - EVP, Finance Rick Matros - CEO, President & Chair Talya Nevo-Hacohen - CIO, Treasurer & EVP Mike Costa - CFO Conference Call Participants Farrell Granath - Bank of America John Kilichowski - Wells Fargo Michael Griffin - Citi Research Austin Wurschmidt - KeyBanc Capital Markets Georgi Dinkov - Mizuho Juan Sanabria - BMO Capital Markets Richard Anderson - Wedbush Alec Feygin - Baird Equity Research Michael Stroyeck - Green Street Aaron Hecht - JMP Securities Omotayo Okusanya - Deutsche Bank Operator Good day. My name is Aaron, and I will be your conference operator for today.
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.33 per share a year ago.
Besides Wall Street's top -and-bottom-line estimates for Sabra (SBRA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Sabra Health Care REIT gets rated buy, agreeing with consensus, and driven heavily by macro-level demand forecasts for skilled nursing facilities. The stock is undervalued on forward P/FFO vs key peers, and is trading close to its moving average now. The firm has investment-grade ratings from Fitch and Moody's agencies.
With the FED's rate cut predictions for 2025, Sabra Health Care REIT offers a buying opportunity for long-term investors, especially retirees and income investors. Sabra's solid fundamentals, including improved occupancy rates and a safe 6% dividend yield, make it an attractive investment despite recent market sell-offs. The REIT's balance sheet has strengthened, with Moody's upgrading their outlook to positive, indicating potential for future investment opportunities and price appreciation.
Sabra (SBRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sabra Health Care REIT offers a compelling investment opportunity with a reasonable valuation, trading at 13.6x 2024 FFO and 12.9x 2025 FFO. The company benefits from strong industry fundamentals, including an aging population and growing demand for senior living and healthcare facilities. Q3'24 results showed robust performance with occupancy gains and NOI growth, particularly in the SHOP portfolio, indicating effective operational leverage.
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q3 2024 Earnings Conference Call November 1, 2024 1:00 PM ET Company Participants Lukas Hartwich - Senior Vice President, Finance Rick Matros - Chief Executive Officer, President & Chair of the Board Talya Nevo-Hacohen - Chief Investment Officer, Treasurer & Executive Vice President Michael Costa - Chief Financial Officer Conference Call Participants Elmer Chang - Scotiabank John Kilichowski - Wells Fargo Austin Wurschmidt - KeyBanc Juan Sanabria - BMO Capital Michael Griffin - Citi Rich Anderson - Wedbush Alec Feygin - Baird Michael Stroyeck - Green Street Omotayo Okusanya - Deutsche Bank Operator Good day, everyone. My name is Adam, and I will be your conference operator today.
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.